-25%
GLP-3-RTA
Price range: $125.00 through $250.00
| Quantity | Price | Discount |
|---|---|---|
| 5-9 | $118.75 | 5% |
| 10-14 | $112.50 | 10% |
| 15-19 | $108.75 | 13% |
| 20+ | $102.50 | 18% |
Peptide Profile
Unlike medications that target only one or two hormones, GLP-3-RTA’s triple-agonist mechanism offers a more comprehensive approach to weight management.
- GLP-1 receptor activation: Increases insulin secretion, decreases glucagon release, and slows gastric emptying. This reduces appetite and helps control blood sugar.
- GIP receptor activation: Enhances insulin secretion in response to high glucose levels and may improve fat metabolism.
- Glucagon receptor activation: Increases energy expenditure and fat oxidation, which is a unique component that may contribute to greater weight loss
Key Highlights
- Ultra-pure, precision-crafted research peptide
- Designed for reliable stability and consistent results
- Manufactured under rigorous quality control standards
- For laboratory research use only
| Size |
20mg ,30mg ,50mg |
|---|
Related Products
AccuInject Peptide Pen
$15.00
Black
Blue
Gold
Pink
Purple
Turquoise
Select options
This product has multiple variants. The options may be chosen on the product page
BAC Water
Price range: $3.50 through $7.50
Select options
This product has multiple variants. The options may be chosen on the product page
GLP-1-SMG
Price range: $50.00 through $80.00
Select options
This product has multiple variants. The options may be chosen on the product page
GLP-2-TRZ
Price range: $80.00 through $185.00
Select options
This product has multiple variants. The options may be chosen on the product page
GLP-3-RTA
Price range: $125.00 through $250.00
Select options
This product has multiple variants. The options may be chosen on the product page
Recently Viewed
3ml Disposable Cartridge
$5.00
AccuInject Peptide Pen
$15.00
BAC Water
Price range: $3.50 through $7.50
Cagrilinitide 10mg
Original price was: $110.00.$95.00Current price is: $95.00.
GHK-Cu 100mg
$65.00
Reviews
There are no reviews yet.